The Dana-Farber/Harvard Cancer Center (DF/HCC) Breast Cancer SPORE Biostatistics and Computational Biology Core (Core B) collaborates and provides consultation on all research activities within the SPORE, including SPORE Projects, Developmental Research Program and Career Development Program projects to ensure the highest standards of scientific rigor in areas of study design, data management and integrity and data analysis and interpretation. The overarching goal is to promote translational research derived from fundamental discoveries in the laboratory that can lead to tangible clinical benefit. In addition, we will collaborate with other SPORE Cores to create an integrated system of resource support for the SPORE and SPORE investigators. Core B will also provide short-term biostatistics and computational biology consulting to the entire group of SPORE researchers. Core B has a wealth of experienced biostatisticians and computational biologists equipped with excellent computational support, including major commercial and public-use statistical software, and a large library of locally written software for design and analysis.
Organizing biostatistical and computational biology expertise as a shared resource core is a cost-effective approach to ensure that collaboration is readily available to SPORE investigators. Core B is effective in guaranteeing a high degree of quality of biostatistical support and integration across the SPORE; including Projects and Cores; which have interrelated analytic goals and needs; enhancing the SPORE?s ability to provide translational research outcomes with tangible clinical benefit.
|Spangle, Jennifer M; Dreijerink, Koen M; Groner, Anna C et al. (2016) PI3K/AKT Signaling Regulates H3K4 Methylation in Breast Cancer. Cell Rep 15:2692-704|
|Montaser-Kouhsari, Laleh; Knoblauch, Nicholas W; Oh, Eun-Yeong et al. (2016) Image-guided Coring for Large-scale Studies in Molecular Pathology. Appl Immunohistochem Mol Morphol 24:431-5|
|Morganella, Sandro; Alexandrov, Ludmil B; Glodzik, Dominik et al. (2016) The topography of mutational processes in breast cancer genomes. Nat Commun 7:11383|
|Cheng, H; Liu, P; Ohlson, C et al. (2016) PIK3CA(H1047R)- and Her2-initiated mammary tumors escape PI3K dependency by compensatory activation of MEK-ERK signaling. Oncogene 35:2961-70|
|Choi, Young Eun; Meghani, Khyati; Brault, Marie-Eve et al. (2016) Platinum and PARP Inhibitor Resistance Due to Overexpression of MicroRNA-622 in BRCA1-Mutant Ovarian Cancer. Cell Rep 14:429-39|
|Ni, Jing; Ramkissoon, Shakti H; Xie, Shaozhen et al. (2016) Combination inhibition of PI3K and mTORC1 yields durable remissions in mice bearing orthotopic patient-derived xenografts of HER2-positive breast cancer brain metastases. Nat Med 22:723-6|
|Wang, Q; Liu, P; Spangle, J M et al. (2016) PI3K-p110Î± mediates resistance to HER2-targeted therapy in HER2+, PTEN-deficient breast cancers. Oncogene 35:3607-12|
|Nik-Zainal, Serena; Davies, Helen; Staaf, Johan et al. (2016) Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature 534:47-54|
|Smid, Marcel; RodrÃguez-GonzÃ¡lez, F GermÃ¡n; Sieuwerts, Anieta M et al. (2016) Breast cancer genome and transcriptome integration implicates specific mutational signatures with immune cell infiltration. Nat Commun 7:12910|
|Johnson, Shawn F; Cruz, Cristina; Greifenberg, Ann Katrin et al. (2016) CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer. Cell Rep 17:2367-2381|
Showing the most recent 10 out of 38 publications